DNA Damage Response Modulators
Our pipeline of DNA Damage Response modulators includes novel inhibitors of ATR and WEE1.
ATRN-119: Novel macrocyclic ATR inhibitor
-
Phase 1 clinical trial expected to commence 3Q, 2022
-
Unique biomarkers identified for optimized patient selection
-
Differentiated, macrocyclic molecular structure
-
Potential for lower hematological toxicity versus other ATR inhibitors
ATRN-W1051: Novel WEE1 inhibitor
-
Structurally differentiated from other WEE1 inhibitors
-
Excellent selectivity for WEE1 versus PLK1/2/3, potentially limiting off-target toxicity
-
Nanomolar anti-proliferative activity against multiple cancer cell lines
-
Promising anti-tumor activity in tumor model
-
Potential for improved PK properties versus other WEE1 inhibitors
-
IND-enabling studies expected to commence in 2H, 2022
DDR PIPELINE
program / target
molecule
discovery
optimization
IND-enabling
phase one
ATR
ATR
WEE1
Novel DDR Target
ATRN-119
Undisclosed
ATRN-W1051
Undisclosed